KR20230136622A - Sgk-1의 저해를 위한 피라졸로[3,4-d]피리미딘-6-일-설폰아미드 유도체 - Google Patents

Sgk-1의 저해를 위한 피라졸로[3,4-d]피리미딘-6-일-설폰아미드 유도체 Download PDF

Info

Publication number
KR20230136622A
KR20230136622A KR1020237027620A KR20237027620A KR20230136622A KR 20230136622 A KR20230136622 A KR 20230136622A KR 1020237027620 A KR1020237027620 A KR 1020237027620A KR 20237027620 A KR20237027620 A KR 20237027620A KR 20230136622 A KR20230136622 A KR 20230136622A
Authority
KR
South Korea
Prior art keywords
group
compound
alkyl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237027620A
Other languages
English (en)
Korean (ko)
Inventor
마크 비달
마루아 칼리파
마틴 매과이어
Original Assignee
쓰리브 테라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쓰리브 테라퓨틱스 인크. filed Critical 쓰리브 테라퓨틱스 인크.
Publication of KR20230136622A publication Critical patent/KR20230136622A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020237027620A 2021-01-13 2022-01-12 Sgk-1의 저해를 위한 피라졸로[3,4-d]피리미딘-6-일-설폰아미드 유도체 Pending KR20230136622A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163136782P 2021-01-13 2021-01-13
US63/136,782 2021-01-13
US202163262040P 2021-10-04 2021-10-04
US63/262,040 2021-10-04
PCT/CA2022/050038 WO2022150911A1 (en) 2021-01-13 2022-01-12 Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1

Publications (1)

Publication Number Publication Date
KR20230136622A true KR20230136622A (ko) 2023-09-26

Family

ID=82446316

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237027620A Pending KR20230136622A (ko) 2021-01-13 2022-01-12 Sgk-1의 저해를 위한 피라졸로[3,4-d]피리미딘-6-일-설폰아미드 유도체

Country Status (8)

Country Link
US (1) US20240309005A1 (enExample)
EP (1) EP4277905A4 (enExample)
JP (1) JP2024502178A (enExample)
KR (1) KR20230136622A (enExample)
CN (1) CN121517419A (enExample)
AU (1) AU2022208639A1 (enExample)
MX (1) MX2023008219A (enExample)
WO (1) WO2022150911A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240155634A (ko) * 2023-04-20 2024-10-29 한국화학연구원 신규한 헤테로고리 화합물 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 포함하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025525475A (ja) * 2022-07-12 2025-08-05 スリブ セラピューティクス インコーポレイテッド Ｎ－［４－（４－［［２－（ジメチルアミノ）エチル］アミノ］－３－メチル－１Ｈ－ピラゾロ［３，４－ｄ］ピリミジン－６－イル）－２－フルオロフェニル］－２，５－ジフルオロベンゼンスルホンアミドの塩及びそれらの結晶形態
WO2024015055A1 (en) * 2022-07-13 2024-01-18 Thryv Therapeutics Inc. Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1 and treatment of cancer
WO2025072438A1 (en) * 2023-09-27 2025-04-03 Bristol-Myers Squibb Company Piperidine substituted pyrazolopyrimidine derivatives as inhibitors of sgk1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5827849B2 (ja) * 2011-09-20 2015-12-02 サノフイ Ｎ−［４−（１Ｈ−ピラゾロ［３，４−ｂ］ピラジン−６−イル）−フェニル］−スルホンアミド及び薬剤としてのその使用
TWI629275B (zh) * 2013-03-13 2018-07-11 賽諾菲公司 Ｎ－（４－（氮雜吲唑－６－基）－苯基）－磺醯胺及其作為醫藥之用途
WO2015048531A1 (en) * 2013-09-26 2015-04-02 Beth Israel Deaconess Medical Center, Inc. Inhibition of sgk1 in the treatment of heart conditions
AU2017373758B2 (en) * 2016-12-07 2021-12-16 Orimos Therapeutics Co., Ltd. Compounds and pharmaceutical compositions for modulating SGK activity, and methods thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240155634A (ko) * 2023-04-20 2024-10-29 한국화학연구원 신규한 헤테로고리 화합물 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 포함하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
WO2022150911A8 (en) 2022-09-09
CA3172186A1 (en) 2022-07-21
EP4277905A1 (en) 2023-11-22
EP4277905A4 (en) 2025-01-01
CN121517419A (zh) 2026-02-13
WO2022150911A1 (en) 2022-07-21
US20240309005A1 (en) 2024-09-19
JP2024502178A (ja) 2024-01-17
AU2022208639A1 (en) 2023-07-20
MX2023008219A (es) 2023-08-24

Similar Documents

Publication Publication Date Title
AU2018200536B2 (en) Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
AU2022349569A1 (en) Pyridine derivative and use thereof
JP5752232B2 (ja) プロテインキナーゼ阻害剤としての置換ピロロトリアジン化合物
JP6212527B2 (ja) Ａｔｒキナーゼのインヒビターとして有用なピラジン誘導体
KR20230136622A (ko) Sgk-1의 저해를 위한 피라졸로[3,4-d]피리미딘-6-일-설폰아미드 유도체
CN112638373A (zh) 细胞周期蛋白依赖性激酶抑制剂
JP2018150358A (ja) Ｔａｎｋ結合キナーゼインヒビター化合物
CA3107365A1 (en) Pyrazine compounds and uses thereof
CN114127063B (zh) 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途
JP7282743B2 (ja) 複素環化合物
AU2019210602A1 (en) Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
JP2026021463A (ja) スルホンアミド化合物
CN101090899B (zh) 用作蛋白激酶抑制剂的2,5和2,6双取代的氮茚类似物
CA3172186C (en) Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1
CN117062817A (zh) 用于抑制sgk-1的吡唑并[3,4-d]嘧啶-6-基-磺酰胺衍生物
WO2024015055A1 (en) Pyrazolo[3,4-d]pyrimidin-6-yl-sulfonamide derivatives for the inhibition of sgk-1 and treatment of cancer
WO2024220399A1 (en) Pyrazolotriazinecarbonitriles useful as kinase inhibitors
CN120457122A (zh) 微管蛋白聚合抑制剂
CN121219292A (zh) 作为sgk1抑制剂的氨基取代的吡咯并三嗪衍生物
HK1110584A (en) 2, 5 and 2, 6-disubstituted benzazole analogues useful as protein kinase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230814

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250107

Comment text: Request for Examination of Application